Resultantly, the peptides could significantly antagonize the SARS-CoV-2 S-RBD: ACE2 interaction, thereby demonstrating the scope of their detailed investigations for the treatment of COVID-19 (Fig. 25) [160]. Here, ACE2 is linked to COVID-19.